Ticker
AGLE

Price
1.27
Stock movement up
+0.03 (2.42%)
Company name
Aeglea Bio Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
77.69M
Ent value
84.57M
Price/Sales
21.31
Price/Book
1.26
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-80.31%
3 year return
-46.89%
5 year return
-21.54%
10 year return
-
Last updated: 2022-11-29

DIVIDENDS

AGLE does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales21.31
Price to Book1.26
EV to Sales23.20

FINANCIALS

Per share

Loading...
Per share data
Current share count61.17M
EPS (TTM)-0.72
FCF per share (TTM)-0.92

Income statement

Loading...
Income statement data
Revenue (TTM)3.65M
Gross profit (TTM)5.06M
Operating income (TTM)-47.46M
Net income (TTM)-47.61M
EPS (TTM)-0.72
EPS (1y forward)-1.00

Margins

Loading...
Margins data
Gross margin (TTM)138.72%
Operating margin (TTM)-1302.05%
Profit margin (TTM)-1305.97%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash14.64M
Net receivables1.01M
Total current assets72.60M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets83.17M
Accounts payable2.98M
Short/Current long term debt4.92M
Total current liabilities16.30M
Total liabilities21.51M
Shareholder's equity61.66M
Net tangible assets61.66M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-60.45M
Capital expenditures (TTM)160.00K
Free cash flow (TTM)-60.61M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-77.21%
Return on Assets-57.24%
Return on Invested Capital-76.65%
Cash Return on Invested Capital-97.58%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.31
Daily high1.31
Daily low1.22
Daily Volume272K
All-time high11.99
1y analyst estimate4.43
Beta1.94
EPS (TTM)-0.72
Dividend per share-
Ex-div date-
Next earnings date6 Mar 2023

Downside potential

Loading...
Downside potential data
AGLES&P500
Current price drop from All-time high-89.41%-17.12%
Highest price drop-96.81%-56.47%
Date of highest drop2 Aug 20229 Mar 2009
Avg drop from high-47.14%-11.46%
Avg time to new high1673 days13 days
Max time to new high1672 days1805 days
COMPANY DETAILS
AGLE (Aeglea Bio Therapeutics Inc) company logo
Marketcap
77.69M
Marketcap category
Small-cap
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Employees
99
Investor relations
-
SEC filings
CEO
Anthony G. Quinn
Country
USA
City
Austin
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Aeglea BioTherapeutics Inc (NASDAQ: AGLE) has appointed Jeffrey M. Goldberg as president, chief executive officer, and a board member, effective November 29, 2022. Jim Kastenmayer will step down as in...
November 30, 2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today a...
November 30, 2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today ...
November 15, 2022
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 3, 2022
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today a...
November 3, 2022
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
October 21, 2022
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
October 21, 2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today annou...
October 19, 2022
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
October 17, 2022
Aeglea BioTherapeutics Inc (NASDAQ: AGLE) received an FDA letter responding to a recently submitted protocol amendment for the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria. Classical ...
October 4, 2022
Next page